Wearable epilepsy technology takes a step forward with Novela‘s acquisition of seizure-detection assets from the aptly-named Brain Sentinel.
Novela’s Neureka® is a wearable, data-centric telemedicine platform giving personalized, continuous epilepsy care. By providing data points on members’ epilepsy Novela aims to empower patients, caregivers, and clinicians with holistic care.
And now, Novela has the complete IP portfolio of Brain Sentinel Inc., former manufacturer of the SeizureLink™ wearable and 510(k)-cleared seizure-monitoring SPEAC® System. The acquisition spans 58 patents and applications and positions Novela at the forefront of epilepsy care.
Epilepsy is the fourth most common neurological disorder, affecting over 70 million people worldwide. While there are many seizure types, motor seizures — including tonic-clonic seizures (TCS) — are particularly dangerous for patients, as they increase the risk of injury and mortality. By gathering continuous data unobtrusively, Novela hopes to change the face of epilepsy medicine.
Read the press release here.
For more information, visit https://www.neureka.ai/.